Search

Displaying results 3911 - 3920 of 4860 in total
  1. Drug

    Picoplatin

    go.drugbank.com/drugs/DB04874
    Investigational

    It causes apoptosis (cell death) by binding to DNA and interfering with DNA replication and transcription.

  2. Drug

    Clinafloxacin

    go.drugbank.com/drugs/DB14025
    Experimental

    It has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.

  3. Drug

    Zinpentraxin alfa

    go.drugbank.com/drugs/DB14852
    Investigational

    It is under investigation in clinical trial NCT01981850 (A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis).

  4. Drug

    MT-0169

    go.drugbank.com/drugs/DB17430
    Investigational

    MT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein.

  5. Drug

    Ligufalimab

    go.drugbank.com/drugs/DB17542
    Investigational

    It is under investigation in clinical trial NCT04900350 (A Trial of AK117 (Anti-cd47) in Patients With Myelodysplastic Syndrome).

  6. Drug

    Exbivirumab

    go.drugbank.com/drugs/DB17747
    Experimental

    It is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies to the hepatitis B virus (HBV) surface antigen.[A259202]

  7. Drug

    AMP-101

    go.drugbank.com/drugs/DB18253
    Experimental

    It is under investigation for the treatment of Dok-7-associated myasthenia.

  8. Drug

    Sodium copper chlorophyllin

    go.drugbank.com/drugs/DB16522
    Investigational

    Sodium copper chlorophyllin (SCC) is a water-soluble and bright green mixture derived from natural chlorophyll that has potential antimutagenic and antioxidant properties . This compound is used as a food colorant and supplement . SCC of...

  9. Drug

    Apadenoson

    go.drugbank.com/drugs/DB05009
    Investigational

    It is developed by Bristol-Myers Squibb and is in phase II of clinical trials.

  10. Drug

    Arylacenamide

    go.drugbank.com/drugs/DB05792
    Experimental

    It is a dual agent with both immunomodulatory and antiproliferative activities.